Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 24.08.2026 1 ACS Omega 1 Adv Sci (Weinh) 1 AJR Am J Roentgenol 1 Am J Surg Pathol 2 Arch Esp Urol 1 Asia Pac J Clin Oncol 1 BJU Int 1 BJUI Compass 1 BMC Anesthesiol 1 BMC Cancer 1 BMC Geriatr 1 Cancer Innov 1 Cancer Sci 1 Clin Exp Med 1 Clin Genitourin Cancer 1 Clin Med Insights Oncol 1 Crit Rev Oncol Hematol 1 Eur J Nutr 4 Eur Urol Oncol 1 Eur Urol Open Sci 1 Front Oncol 2 Int J Urol 1 Iran J Microbiol 1 J Clin Invest 1 J Med Econ 1 J Neurooncol 1 JCO Glob Oncol 1 Lab Invest 1 Mater Today Bio 1 Med Oncol 1 Oncologist 1 Oncotarget 1 Psychooncology 1 Radiother Oncol 1 Soc Sci Med 3 Urol Oncol 1 World J Mens Health 2 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Omega

1. ZEMLA J, Smialek-Bartyzel J, Brzuchacz B, Lekka M, et al
   Lectin-Micropatterned Biointerfaces Regulate Cytoskeletal Organization and Viscoelastic Phenotypes of Bladder Cancer Cells.
   ACS Omega. 2026;11:48215-48229.
   PubMed         Abstract available
   
   

   
   Adv Sci (Weinh)

2. LI R, Zhao A, Zhuang Q, Peng L, et al
   An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer.
   Adv Sci (Weinh). 2026 Aug 17:e77241. doi: 10.1002/advs.77241.
   PubMed         Abstract available
   
   

   
   AJR Am J Roentgenol

3. WANG W, He J, Wu J, Li W, et al
   Photon-Counting CT With Low-keV Virtual Monoenergetic Images for Detecting Muscle Invasion in Bladder Cancer: A Prospective Study.
   AJR Am J Roentgenol. 2026 Aug 19. doi: 10.2214/AJR.26.35310.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

4. CHENG L, Tan HM, Lopez-Beltran A, Montironi R, et al
   Urothelial Carcinoma in Children and Young Adults is Characterized by Higher Frequency of HRAS Mutations and Lower Prevalence of TERT Promoter and FGFR3 Mutations.
   Am J Surg Pathol. 2026;50:999-1006.
   PubMed         Abstract available
   
   

   
   Arch Esp Urol

5. LIU Y, Li Y, Wu T, Hu H, et al
   Comparative Analysis of Disease Burden and Risk Factor Attribution for Urological Cancers in Six High-Growth GBD Regions.
   Arch Esp Urol. 2026;79:1014-1026.
   PubMed         Abstract available
   
   
6. ALFIERI AG, Ramirez F, Favre G, Tobia Gonzalez I, et al
   Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Early Radical Cystectomy in Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort From a Latin American Referral Center.
   Arch Esp Urol. 2026;79:915-921.
   PubMed         Abstract available
   
   

   
   Asia Pac J Clin Oncol

7. LUO H, Xu C, Huang S, Wang T, et al
   Exploring Long Noncoding RNA CASC11 as a Biomarker for Bladder Cancer Detection.
   Asia Pac J Clin Oncol. 2026 Aug 17. doi: 10.1111/ajco.70139.
   PubMed         Abstract available
   
   

   
   BJU Int

8. CELLA L, Contieri R, Paciotti M, Fasulo V, et al
   Artificial intelligence for predicting BCG response in non-muscle-invasive bladder cancer: a systematic review.
   BJU Int. 2026 Aug 17. doi: 10.1111/bju.70404.
   PubMed         Abstract available
   
   

   
   BJUI Compass

9. BURGESS EF, Elom H, Brown LC, McCormack M, et al
   The impact of ERBB2 alterations in muscle-invasive bladder cancer after neoadjuvant chemotherapy.
   BJUI Compass. 2026;7:e70274.
   PubMed        
   
   

   
   BMC Anesthesiol

10. UCHINO T, Miura M, Shingu C, Shin T, et al
    Ultrasound versus nerve stimulation-guided interadductor approach for obturator nerve block: evaluation of injectate spread into the obturator canal in a randomized controlled trial.
    BMC Anesthesiol. 2026;26:501.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. WANG T, Jiang X
    Toripalimab plus disitamab vedotin versus tislelizumab-based combination in advanced urothelial carcinoma: a real-world comparative study.
    BMC Cancer. 2026;26:997.
    PubMed         Abstract available
    
    

    
    BMC Geriatr

12. FAYOLLE E, Baudot A, Chaneliere-Sauvant AF, Favier E, et al
    Effectiveness of a personalised 6-month programme on physical frailty in older patients treated for bladder or kidney cancer - FRAGECO program - multicenter, controlled, randomized study protocol.
    BMC Geriatr. 2026;26:1067.
    PubMed         Abstract available
    
    

    
    Cancer Innov

13. LI Z, Li S, Liu Z, Sun Y, et al
    BACE2 Promotes Bladder Cancer Chemoresistance Through Proteolytic Activation of JAG1-Notch Signaling.
    Cancer Innov. 2026;5:e70073.
    PubMed         Abstract available
    
    

    
    Cancer Sci

14. GAN J, Bai X, Zhang A, Lin F, et al
    TRIM59 Drives Bladder Cancer Progression Through E3 Ligase-Dependent K48-Linked Degradation of PTRF.
    Cancer Sci. 2026 Aug 21. doi: 10.1111/cas.70510.
    PubMed         Abstract available
    
    

    
    Clin Exp Med

15. XIN S, Li G, Yang X, Su J, et al
    Identifying PLAU as a shared pathogenic gene in type 2 diabetes and bladder urothelial carcinoma through integrated transcriptomic analysis and machine learning for diagnostic and therapeutic value.
    Clin Exp Med. 2026;26:298.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

16. IRANMAHBOUB P, Dave P, Levine J, Wang S, et al
    The Contemporary Pattern of Radical Cystectomy in the Treatment of High-Grade Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Jul 24:102627. doi: 10.1016/j.clgc.2026.102627.
    PubMed         Abstract available
    
    

    
    Clin Med Insights Oncol

17. SHI Y, Luo X, Huang Y, Tan C, et al
    The Impact of Chronic Kidney Disease on Postoperative Outcomes in Patients With Bladder Cancer: A Meta-Analysis.
    Clin Med Insights Oncol. 2026;20:11795549261479103.
    PubMed         Abstract available
    
    

    
    Crit Rev Oncol Hematol

18. MERCIER J, Cornillon P, Barthelemy P, Leon P, et al
    Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group.
    Crit Rev Oncol Hematol. 2026;225:105505.
    PubMed         Abstract available
    
    

    
    Eur J Nutr

19. VRIELING A, Kiebach J, Balvers M, Aben KK, et al
    Fruit and vegetable consumption, dietary and plasma carotenoids and risks of recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Eur J Nutr. 2026;65:237.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

20. CONTIERI R, Hurle R
    Reply to Pietro scilipoti, Giuseppe Rosiello, Andrea Salonia, Alberto Briganti, Marco Moschini, Francesco Montorsi Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can
    Eur Urol Oncol. 2026 Aug 17:S2588-9311(26)00218.
    PubMed        
    
    
21. DI BELLO F, Gallioli A, Palou J, Breda A, et al
    Re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol O
    Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00230.
    PubMed        
    
    
22. KARDOUST PARIZI M, Shariat SF
    Reply to Simone Sforza's Letter to the Editor re: Mehdi Kardoust Parizi, David D'Andrea, Benjamin Pradere, et al. Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of
    Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00231.
    PubMed        
    
    
23. SCARPA RM
    Re: Contieri R, Paciotti M, Uleri A, et al. Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol. 2026;9:404-412.
    Eur Urol Oncol. 2026 Aug 21:S2588-9311(26)00229.
    PubMed        
    
    

    
    Eur Urol Open Sci

24. ANDREASEN TG, Strandgaard T, Divita TJ, Young-Halvorsen K, et al
    Impact of Photodynamic Diagnosis on Immune Cell Infiltration in BCG-treated Non-muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2026;91:74-83.
    PubMed         Abstract available
    
    

    
    Front Oncol

25. WANG X, Li Z, Zhang B
    Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.
    Front Oncol. 2026;16:1821922.
    PubMed         Abstract available
    
    

    
    Int J Urol

26. ALMULLA AF, Zhang Y, Maes M
    Editorial Comment on "Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression": Rethinking the Tryptophan-Kynurenine Pathway in Urological Cancer Immunotherapy.
    Int J Urol. 2026;33:e70606.
    PubMed        
    
    
27. WAKITA N, Hara T, Tobe T, Ueki H, et al
    Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.
    Int J Urol. 2026;33:e70614.
    PubMed         Abstract available
    
    

    
    Iran J Microbiol

28. KHATAMI F, Mohammadi A, Azadmanesh K, Deyhimfar R, et al
    Updated oncolytic viruses for the treatment of bladder cancer: a systematic review.
    Iran J Microbiol. 2026;18:448-459.
    PubMed         Abstract available
    
    

    
    J Clin Invest

29. CHEN C, Zheng H, Luo Y, Kong Y, et al
    Corrigendum to SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1? ?and lymph node metastasis in bladder cancer.
    J Clin Invest. 2026;136:e210810.
    PubMed        
    
    

    
    J Med Econ

30. HILL-MCMANUS D, Lai Y, Bensimon AG, Young J, et al
    Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States.
    J Med Econ. 2026;29:2161-2176.
    PubMed         Abstract available
    
    

    
    J Neurooncol

31. MANORANJAN B, Zeller S, Price H, Reiner AS, et al
    Clinical and genomic characterization of brain metastasis in bladder cancer.
    J Neurooncol. 2026;179:44.
    PubMed         Abstract available
    
    

    
    JCO Glob Oncol

32. SUNDRIYAL D, Prasath S, Prakash HS, Swamy AM, et al
    Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting.
    JCO Glob Oncol. 2026;12:e2600219.
    PubMed         Abstract available
    
    

    
    Lab Invest

33. COLLINS K, Cheng L
    FGFR3-Altered Urothelial Carcinoma: Clinicopathologic Observations With Emphasis on Variant Histology.
    Lab Invest. 2026;106:106133.
    PubMed         Abstract available
    
    

    
    Mater Today Bio

34. FU X, Liang Y, Xu B, Huang C, et al
    A synergistic cascade nanoreactor breaks bladder cancer chemoresistance: Synergizing cholesterol metabolism reprogramming with cGAS-STING-mediated metallotherapy.
    Mater Today Bio. 2026;40:103537.
    PubMed         Abstract available
    
    

    
    Med Oncol

35. PRASATH S, Sundriyal D, Harsha SP, Swamy AM, et al
    Feasibility and safety of accelerated MVAC (aMVAC) in geriatric patients with muscle-invasive bladder cancer.
    Med Oncol. 2026;43:248.
    PubMed         Abstract available
    
    

    
    Oncologist

36. AZARI S, Salmasi A, Stewart T
    Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer: unprecedented outcomes from KEYNOTE-B15.
    Oncologist. 2026 Aug 19:oyag332. doi: 10.1093.
    PubMed        
    
    

    
    Oncotarget

37. CRANE K, Bhat KRS, Grivas P, Necchi A, et al
    Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine.
    Oncotarget. 2026;17:381-387.
    PubMed         Abstract available
    
    

    
    Psychooncology

38. HUANG CS, Tung KH, Wu YS, Yu CP, et al
    Association of Postoperative Antidepressant and Anxiolytic Exposure With Overall Survival Following Radical Cystectomy for Bladder Cancer.
    Psychooncology. 2026;35:e70581.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

39. YUAN Q, Xing X, Ma Z, Shang P, et al
    Radiotherapy for female non-gynecologic pelvic and adjacent cancers and secondary uterine Cancers: a SEER analysis.
    Radiother Oncol. 2026;222:111697.
    PubMed         Abstract available
    
    

    
    Soc Sci Med

40. XU H, Han X, Zhang Y, Liu X, et al
    When uncertainty becomes guilt: The moralisation of home urinary stoma care after bladder cancer surgery in China.
    Soc Sci Med. 2026;407:119667.
    PubMed         Abstract available
    
    

    
    Urol Oncol

41. LIU X, Fu K, Xiong L, Liu X, et al
    Clinicopathological features and prognosis of plasmacytoid urothelial carcinoma of the bladder: A retrospective analysis of 36 cases.
    Urol Oncol. 2026;44:412-421.
    PubMed         Abstract available
    
    
42. NANDWANA D, Siva J, Davis L, Sindhani M, et al
    Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.
    Urol Oncol. 2026;44:211-222.
    PubMed         Abstract available
    
    
43. MOHAMED T, Mohamed H, Deameh MG, Irshid BAB, et al
    Ileal conduit vs. orthotopic ileal neobladder after radical cystectomy: Systematic review and meta-analysis of long-term renal function.
    Urol Oncol. 2026;44:147-157.
    PubMed         Abstract available
    
    

    
    World J Mens Health

44. LIN YH
    Beyond Symptom Relief: A Dual-Mechanism Hypothesis Linking Definitive Bladder Outlet Obstruction Relief to Bladder Cancer Control.
    World J Mens Health. 2026 Aug 7. doi: 10.5534/wjmh.260171.
    PubMed        
    
    

    
    World J Urol

45. PFAIL J, O'Leary C, Fu M, Kaldany A, et al
    The impact of intraoperative ureteral stent omission on postoperative complications during radical cystectomy.
    World J Urol. 2026;44:593.
    PubMed         Abstract available
    
    
46. HE Q, Jiang Z, Jiang C, Tu X, et al
    Bladder preservation vs. radical cystectomy for T2N0M0: trends and survival outcomes from SEER.
    World J Urol. 2026;44:575.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum